Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:2154 |
| Name | nephroblastoma |
| Definition | A kidney cancer that affects the kidneys and typically occuring in children. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:5180 DOID:5177 |
| Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer nephroblastoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| TP53 mutant | N/A | nephroblastoma | not applicable | detail... |
| BRAF V600E | Dabrafenib | nephroblastoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
| NCT01661400 | Phase I | Cyclophosphamide Thalidomide | Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors | Completed | USA | 0 |
| NCT02789228 | Phase I | MultiTAA-specific T cells | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) | Active, not recruiting | USA | 0 |
| NCT02982941 | Phase I | Enoblituzumab | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Completed | USA | 0 |
| NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
| NCT03838042 | Phase Ib/II | Entinostat + Nivolumab | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) | Recruiting | SWE | NLD | FRA | DEU | CHE | AUT | AUS | 0 |
| NCT04851119 | Phase Ib/II | Tegavivint | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
| NCT05064306 | Expanded access | Omburtamab I-131 | 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults | No longer available | USA | 0 |
| NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib As a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
| NCT05985161 | Phase II | Selinexor | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Recruiting | USA | 0 |
| NCT06500819 | Phase I | B7H3 CAR-T cells | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors | Recruiting | USA | 0 |